Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk

References

• Sahin NH, Bal MD, Boğğa NM, et al. Women’s perception of the menopause and hormone treatment: barriers against hormone therapy. Climacteric. 2011;14(1):152–156.
   PubMed Web of Science ®Google Scholar
• NHLBI Communications Office. NHLBI Stops Trial of Estrogen Plus Progestin Due to Increased Breast Cancer Risk, Lack of Overall Benefit. July 8, 2002. http://www.nhlbi.nih.gov/new/press/02-07-09.htm.
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Writing group for the women’s health initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al. WHI investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s health initiative randomized trial. JAMA. 2003;289(24):3243–3253.
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009;113(1):65–73.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant Meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873.
   PubMed Web of Science ®Google Scholar
• Brown S. Shock, terror and controversy: how the media reacted to the women’s health initiative. Climacteric. 2012;15(3):275–280.
   PubMed Web of Science ®Google Scholar
• Reid RL. Hormone therapy and breast cancer: risk communication and the 'perfect storm. Climacteric. 2019;22(1):13–16.
   PubMed Web of Science ®Google Scholar
• Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the national health and nutrition examination survey, 1999–2010. Obstet Gynecol. 2012;120(3):595–603.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. WHI investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–1692.
   PubMed Web of Science ®Google Scholar
• Bhupathiraju SN, Manson JE. Menopausal hormone therapy and chronic disease risk in the WHI: is timing everything? Endocr Pract. 2014;20(11):1201–1213.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials. JAMA. 2020;324(4):369–380.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Women’s health initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. WHI investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):1647–1657.
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. WHI investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305–1314.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the women's health initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476–486.
   PubMed Web of Science ®Google Scholar
• CIOMS III. Guidelines for Preparing Core Clinical-Safety Information on Drugs, ed 2. 1999.
   Google Scholar
• Breast Cancer Facts & Figures 2019-2020. American Cancer Society. Available from https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2019-2020.pdf.
   Google Scholar
• Santen RJ, Petroni GR. Relative versus attributable risk of breast cancer from estrogen replacement therapy. J Clin Endocrinol Metab. 1999;84(6):1875–1881.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M., et al., eds. SEER cancer statistics review, 1975-2014. Bethesda, MD: National Cancer Institute; April 2017.
   Google Scholar
• Climént-Palmer M, Spiegelhalter D. Hormone replacement therapy and the risk of breast cancer: How much should women worry about it? Post Reprod Health. 2019;25(4):175–178.
   PubMedGoogle Scholar
• Phillips KA, Glendon G, Knight JA. Putting the risk of breast cancer in perspective. N Engl J Med. 1999;340(2):141–144.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Beral V. Million women study collaborators. Breast cancer and hormone replacement therapy in the million women study. Lancet. 2003;362(9382):419–427.
   PubMed Web of Science ®Google Scholar
• Davis SR. Menopausal hormone therapy: is there cause for concern? Lancet Diabetes Endocrinol. 2019;7(11):825–827.
   PubMed Web of Science ®Google Scholar
• Yang Z, Hu Y, Zhang J, et al. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and Meta-analysis. Gynecol Endocrinol. 2017;33(2):87–92.
   PubMed Web of Science ®Google Scholar
• Formoso G, Perrone E, Maltoni S, et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10:CD008536.
   PubMedGoogle Scholar
• Stevenson JC, Hodis HN, Pickar JH, et al. HRT and breast cancer risk: a realistic perspective. Climacteric. 2011;14(6):633–636.
   PubMed Web of Science ®Google Scholar
• Lambrinoudaki I, Armeni E. Menopausal hormone therapy and breast cancer: need to put risks in perspective. Maturitas. 2020;131:89–90.
   PubMed Web of Science ®Google Scholar
• Lee IM, Shiroma EJ, Lobelo F, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219–229.
   PubMed Web of Science ®Google Scholar
• Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338–2366.
   PubMed Web of Science ®Google Scholar
• Chan DSM, Abar L, Cariolou M, et al. World cancer research fund international: continuous update project-systematic literature review and Meta-analysis of observational cohort studies on physical activity, sedentary behavior, adiposity, and weight change and breast cancer risk. Cancer Causes Control. 2019;30(11):1183–1200.
   PubMed Web of Science ®Google Scholar
• Hamajima N, Hirose K, Tajima K, et al. Collaborative group on hormonal factors in breast cancer. Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87(11):1234–1245.
   PubMed Web of Science ®Google Scholar
• Lambrinoudaki I, Brincat M, Erel CT, et al. EMAS position statement: managing obese postmenopausal women. Maturitas. 2010;66(3):323–326.
   PubMed Web of Science ®Google Scholar
• Speroff L. Postmenopausal hormone therapy and breast cancer: a clinician’s message for patients. ENDO. 2004;24(3):211–216.
   Google Scholar
• Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. BJOG. 1990;97(12):1080–1086.
   Google Scholar
• Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991;151(1):75–78.
   PubMedGoogle Scholar
• Willis DB, Calle EE, Miracle-McMahill HL Jr., et al. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control. 1996;7(4):449–457.
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336(25):1769–1775.
   PubMed Web of Science ®Google Scholar
• Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127(11):973–980.
   PubMed Web of Science ®Google Scholar
• Schairer C, Gail M, Byrne C, et al. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst. 1999;91(3):264–270.
   PubMedGoogle Scholar
• Rodriguez C, Calle EE, Patel AV, et al. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol. 2001;153(2):145–152.
   PubMed Web of Science ®Google Scholar
• O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93(10):754–762.
   PubMedGoogle Scholar
• Chen W, Petitti DB, Geiger AM. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study. Br J Cancer. 2005;93(4):392–398.
   PubMed Web of Science ®Google Scholar
• Obi N, Heinz J, Seibold P, et al. Relationship between menopausal hormone therapy and mortality after breast cancer. The MARIEplus study, a prospective case cohort. Int J Cancer. 2016;138(9):2098–2108.
   PubMed Web of Science ®Google Scholar
• Mikkola TS, Savolainen-Peltonen H, Tuomikoski P, et al. Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative study. Menopause. 2016;23(11):1199–1203.
   PubMed Web of Science ®Google Scholar
• Wang T, Bradshaw PT, Moorman PG, et al. Menopausal hormone therapy use and long-term all-cause and cause-specific mortality in the Long Island breast cancer study project. Int J Cancer. 2020;147(12):3404–3415.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL. Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf. 2015;6(2):45–56.
   PubMed Web of Science ®Google Scholar
• Beral V, Peto R, Pirie K, et al. Menopausal hormone therapy and 20-year breast cancer mortality. Lancet. 2019;394(10204):1139.
   PubMed Web of Science ®Google Scholar
• Islam S, Liu Q, Chines A, et al. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000–2005. Menopause. 2009;16(1):77–83.
   PubMed Web of Science ®Google Scholar
• Karim R, Dell RM, Greene DF, et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause. 2011;18(11):1172–1177.
   PubMed Web of Science ®Google Scholar
• Sarrel PM, Njike VY, Vinante V, et al. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013;103(9):1583–1588.
   PubMed Web of Science ®Google Scholar
• Sarrel PM. A call to increase the use of hormone therapy to prevent disease in symptomatic postmenopausal women. Menopause. 2019;26(6):573–575.
   PubMed Web of Science ®Google Scholar
• Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol. 2001;98(3):498–508.
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Pramesh CS, Buyse M. Common pitfalls in statistical analysis: "P" values, statistical significance and confidence intervals. Perspect Clin Res. 2015;6(2):116–117.
   PubMedGoogle Scholar
• Santen RJ, Stuenkel CA, Burger HG, et al. Competency in menopause management: whither goest the internist? J Womens Health. 2014;23(4):281–285.
   Web of Science ®Google Scholar
• Constantine GD, Graham S, Clerinx C, et al. Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five european countries. Post Reprod Health. 2016;22(3):112–122.
   PubMedGoogle Scholar
• Manson JE, Kaunitz AM. Menopause management–getting clinical care back on track. N Engl J Med. 2016;374(9):803–806.
   PubMed Web of Science ®Google Scholar
• Hill K. The demography of menopause. Maturitas. 1996;23(2):113–127.
   PubMed Web of Science ®Google Scholar
• Davis SR. Menopause – a new beginning. Climacteric. 2018;21(4):306–307.
   PubMed Web of Science ®Google Scholar
• Shapiro S, de Villiers TJ, Pines A, et al. Risks and benefits of hormone therapy: has medical dogma now been overturned? Climacteric. 2014;17(3):215–222.
   PubMed Web of Science ®Google Scholar
• Bluming AZ, Tavris C. Chains of evidence, mosaics of data: does estrogen ‘cause’ breast cancer? How would we know? Climacteric. 2012;15(6):531–537.
   PubMed Web of Science ®Google Scholar
• Bluming A, Tavris C. Once and for all: Hormone replacement is good for women. Los Angeles: Los Angeles Time; 2019.
   Google Scholar
• Utian WH. Reflections on a life in menopause. Menopause. 2018;25(2):121–126.
   PubMed Web of Science ®Google Scholar
• Neves-E-Castro M. Letter to the editors: My dream. Climacteric. 2004;7:322–323.
   PubMed Web of Science ®Google Scholar